Medpace Holdings, a contract research organization, reported first‑quarter 2026 revenue of $706.6 million, a 26.5% year‑over‑year increase, and net income of $123.9 million, translating to earnings per share of $4.28. The results beat analyst expectations. The company’s net book‑to‑bill ratio for the quarter was 0.88x, and its backlog stood at $2.929 billion as of March 31 2026.
The results reflected a 23.7% rise in net new business awards to $618.4 million, driven by continued demand in Medpace’s metabolic, oncology, and CNS segments. The company maintained a 21.1% EBITDA margin, indicating strong operating efficiency even as pass‑through costs associated with its expanding metabolic portfolio increased.
Medpace reaffirmed its full‑year 2026 guidance, projecting revenue of $2.755 billion to $2.855 billion and diluted earnings per share of $16.68 to $17.50. The guidance signals management confidence in sustaining growth momentum while managing cost pressures.
The company also announced that President Jesse Geiger will retire effective May 31 2026, with CEO August Troendle assuming the president role until a successor is named. The leadership transition is expected to provide continuity as the company continues to expand its service offerings.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.